DLTR
52
8
KMI
69
8
IPG
43
3
CMA
42
3
T
32
2
SPG
45
2
UPS
51
6
CAH
44
7
MCD
52
3
JBHT
46
4
ILMN
31
4
NRG
32
5
DTE
49
16
SLB
41
2
NDAQ
46
2
LEN
21
3
SIG
52
5
BK
60
2
CLX
65
2
PM
49
8
DLTR
52
8
KMI
69
8
IPG
43
3
CMA
42
3
T
32
2
SPG
45
2
UPS
51
6
CAH
44
7
MCD
52
3
JBHT
46
4
ILMN
31
4
NRG
32
5
DTE
49
16
SLB
41
2
NDAQ
46
2
LEN
21
3
SIG
52
5
BK
60
2
CLX
65
2
PM
49
8
Financhill
Back

BridgeBio Pharma 10K Form

Sell
39

BBIO
BridgeBio Pharma

Last Price:
$26.49
Seasonality Move:
-20.12%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BBIO News And Ratings

See the #1 stock for the next 7 days that we like better than BBIO

BBIO Financial Statistics

Sales & Book Value

Annual Sales: $9.3M
Cash Flow: $-182.3M
Price / Cash Flow: 0
Annual Sales: $-6.51
Price / Book: 0

Profitability

EPS (TTM): -2.41000
Net Income (TTM): $-438.9M
Gross Margin: $6.9M
Return on Equity: 0%
Return on Assets: -62.51%

BridgeBio Pharma Earnings Forecast

Key BridgeBio Pharma Financial Ratios

  • The Gross Profit Margin over the past 7 years for BBIO is 73.71%.
  • The Selling, General & Administrative Expenses for BBIO have been equal to 1,618.73% of Gross Profit Margin.
  • The Research & Development expenses have been 4,898.54% of Revenue.
  • The Interest Expense is -12.64% of Operating Income.
  • The Net Earning history of BBIO is -6,913.92% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 1 years.

BridgeBio Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BBIO
CUSIP: 10806X
Website: bridgebio.com

Debt

Debt-to-Equity Ratio: -1.4
Current Ratio: 3.19
Quick Ratio: 1.92

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BBIO Technical Analysis vs Fundamental Analysis

Sell
39
BridgeBio Pharma (BBIO) is a Sell

Is BridgeBio Pharma a Buy or a Sell?

  • BridgeBio Pharma stock is rated a Sell
    The current BridgeBio Pharma [BBIO] share price is $26.50. The Score for BBIO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.